On November 17, a Bangkok delegation led by Torsak Chotimongkol, Chairman of the Bangkok Metropolitan Administration (BMA) Advisory Board, and accompanied by Deputy Mayors Wisanu Subsompon and Sanon Wangsrangboon, visited BGI Group’s headquarters in Shenzhen for in-depth discussions. Senior BGI Group executives welcomed the visitors.
The Bangkok delegation, led by Torsak Chotimongkol (center), Chairman of the Bangkok Metropolitan Administration (BMA) Advisory Board, and accompanied by Deputy Mayors Wisanu Subsompon (third from left) and Sanon Wangsrangboon (second from left), visited BGI Group’s headquarters and met with senior BGI Group executives.
The visit aimed to deepen understanding of BGI Group’s cutting-edge technological capabilities and industrial development, with a particular focus on exploring future avenues of cooperation in critical public health initiatives, including colorectal cancer screening and thalassemia prevention and control.
BGI Group leadership highlighted the company’s decade-long collaboration with Thailand, tracing the partnership’s development from public health program launches to the cultivation of local expertise. Guided by its mission of “Omics for All,” BGI Group has been working with local partners to integrate innovative technologies into Thailand’s public health initiatives.
Thalassemia, Thailand’s most common inherited blood disorder, presents a substantial medical and economic challenge for families and society. In recent years, BGI Group has actively collaborated with the Thai government and local partners to address this critical issue. Drawing on world-leading genomic sequencing technology and extensive expertise in public health screening, BGI Group has contributed to advancing thalassemia prevention and control and improving public health outcomes.
A key topic of discussion was bringing BGI Group’s advanced non-invasive colorectal cancer genetic screening technology to Thailand. This innovative approach enables accurate risk assessment for colorectal cancer through convenient at-home sampling. Combining convenience, precision, and high accessibility, it is well-suited for public cancer screening and is expected to significantly enhance Thailand’s capabilities in early diagnosis and treatment of colorectal cancer.
Chairman Chotimongkol praised BGI Group’s pioneering work in genomic technology. He noted that the BMA has made public health a core priority and launched an all-ages health screening program covering one million residents in January 2024. He stated that BGI Group’s technological strength and extensive experience in global public health initiatives are impressive, and that the Thai partners will firmly support BGI Group’s continued development in Thailand. He expressed hope that BGI Group will introduce more innovative technologies and successful models to Thailand to jointly enhance the health and well-being of the Thai people.
Looking ahead, BGI Group remains committed to an open and collaborative approach. BGI Group will continue working closely with Thai partners to drive the innovative application of leading-edge technologies in areas such as disease prevention and precision medicine.